GLP-3 R Phase 2: −28.7%143 Compounds · 5 Layers>98% HPLC All VialsFree Shipping $200+Third-Party Test ReportsResearch Use OnlyCAS Numbers VerifiedGHK-Cu: 4,000+ GenesGLP-3 R Phase 2: −28.7%143 Compounds · 5 Layers>98% HPLC All VialsFree Shipping $200+Third-Party Test ReportsResearch Use OnlyCAS Numbers VerifiedGHK-Cu: 4,000+ Genes
Ipamorelin/Tesamorelin Blend 13mg

Ipamorelin/Tesamorelin Blend 13mg

Ipamorelin + Tesamorelin

CAS: 170851-70-4 / 218949-48-5

$116.99$129.9910% OFFIn Stock

Ipamorelin 3mg + Tesamorelin 10mg blend — lower-ratio Ipamorelin variant for research designs emphasizing tesamorelin-driven GHRH activity with minimal GHS-R1a confounding. 99.0% HPLC purity.

Specifications

Ipamorelin3mg
Tesamorelin10mg
FormLyophilized Powder
Purity99.0% HPLC
Storage-20C long-term
Shop This Compound

For laboratory research use only. Not for human consumption.

Mechanism of Action

Tesamorelin-dominant blend. 10mg Tesamorelin provides primary GHRH-mediated GH stimulation; 3mg Ipamorelin adds a measured GHS-R1a frequency component.

Research FAQ

When to choose 13mg vs 15mg IPA/TESA blend?

The 13mg (3mg IPA) is preferred when the research focus is primarily on Tesamorelin GHRH effects with minimal GHSR confounding. The 15mg (5mg IPA) provides more balanced dual-receptor coverage.

Related Compounds